Last reviewed · How we verify
Peflacine (PEFLOXACIN)
Pefloxacin works by inhibiting bacterial DNA replication, ultimately killing the bacteria.
Pefloxacin, also known as Peflacine, is a small molecule antibiotic in the fluoroquinolone class. It targets the Cytochrome P450 1A2 enzyme, but its primary mechanism is as a bactericidal agent that inhibits DNA gyrase and topoisomerase IV, essential for bacterial DNA replication. Pefloxacin is used to treat various bacterial infections, but its commercial status and approved indications are unknown. The drug has a bioavailability of 90% and a half-life of 11.0 hours. As a generic or patented product is unknown, further information is required to determine its availability.
At a glance
| Generic name | PEFLOXACIN |
|---|---|
| Drug class | pefloxacin |
| Target | Cytochrome P450 1A2, DNA gyrase subunit A, DNA gyrase subunit B |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Imagine your body's cells are like factories that make copies of themselves. Bacteria are like tiny factories that make copies of themselves too, but they can cause harm. Pefloxacin stops these bacterial factories from making copies of themselves by interfering with their DNA, which ultimately kills the bacteria.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peflacine CI brief — competitive landscape report
- Peflacine updates RSS · CI watch RSS